fda announcement semaglutide Oral Gets Approval for CV Event Reduction in High-risk Diabetes Patients Novo Nordisk introduces NovoCare® Pharmacy,

[4] Without continued treatment, most patients regain 6080% of lost weight within 12 years

The pharmacokinetic gap between peak tirzepatide effect and peak semaglutide effect creates a vulnerable window where appetite suppression decreases and weight regain risk increases

This GIP-mediated enhancement of central GLP-1 delivery is a unique feature not available to mono-agonists, ensuring a more potent engagement of central pathways

For some people, staying at the same dose for a few weeks before increasing may give the digestive system more time to adapt and reduce the intensity of side effects like constipation, nausea, or bloating, says Hamilton

L.BujarskiJ